Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid ...

Novo Nordisk executive vice president for Commercial Strategy & Corporate Affairs, Camilla Sylvest says the company plans to ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Health-care companies slipped, as traders rotated back into sectors more associated with artificial-intelligence developments. Novo Nordisk said the Food and Drug Administration approved the ...

However, inclusion does not solve access or out-of-pocket costs issues for commercial and uninsured ... Future of Healthcategory US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

Despite these results, Novo Nordisk's stock experienced a downturn, which may reflect investor concerns over the commercial implications or regulatory prospects of the new dosage. The trial ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in ...